Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis

Trial Profile

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary)
  • Indications Deep vein thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms ARM-DVT
  • Sponsors Intermountain Healthcare

Most Recent Events

  • 26 Sep 2023 Status changed from suspended to discontinued.
  • 24 Aug 2021 Status changed from recruiting to suspended due to COVID-19 resource allocation.
  • 11 Feb 2020 Planned End Date changed from 1 Oct 2019 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top